Cipla shares fell as much as 2.5% on July 22, 2026. Other prominent Indian pharmaceutical stocks also declined during the session.
The sell-off follows US President Donald Trump’s proposal to impose 100% to 200% tariffs on generic drug imports. These levies are scheduled to take effect in 2028.
Investors fear the tariffs will impact future earnings from the US, which remains a critical export market for Cipla. A recent report also confirmed that Cipla’s quarterly and annual profits declined during the 2026 fiscal year.
The company’s board will meet on July 23, 2026, to review first-quarter results for FY27. Markets are monitoring the upcoming report for indications of how the company will navigate these trade challenges.